For research use only. Not for therapeutic Use.
AES-350（Cat No.:I021446）is an investigational therapeutic agent under development, primarily aimed at treating inflammatory and autoimmune diseases. It functions by selectively modulating immune responses, offering potential benefits in conditions characterized by chronic inflammation. By targeting specific pathways involved in immune regulation, AES-350 helps reduce inflammation while minimizing adverse effects commonly seen with broad-spectrum immunosuppressants. Its efficacy in preclinical studies has positioned it as a promising candidate for further clinical trials, with the potential to provide a new treatment option for patients with autoimmune disorders.
| Catalog Number | I021446 |
| CAS Number | 847249-57-4 |
| Synonyms | AES-350; AES 350; AES350; |
| Molecular Formula | C18H20N2O3 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
| IUPAC Name | 4-(tert-butyl)-N-(4-(hydroxycarbamoyl)phenyl)benzamide |
| InChI | InChI=1S/C18H20N2O3/c1-18(2,3)14-8-4-12(5-9-14)16(21)19-15-10-6-13(7-11-15)17(22)20-23/h4-11,23H,1-3H3,(H,19,21)(H,20,22) |
| InChIKey | FMOQHLZNJFXULZ-UHFFFAOYSA-N |
| SMILES | CC(C)(C)C1=CC=C(C(NC2=CC=C(C(NO)=O)C=C2)=O)C=C1 |
